Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -8.70% is 81% above its 5-year average of -46.82%, near the high end of its 5-year range (-157.98%–9.64%).
237.33% below its 12-month average of 6.33%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.32%.
RETURN ON ASSETS (ROA)
-8.70%
RETURN ON ASSETS (ROA) AVG TTM
6.33%
RETURN ON ASSETS (ROA) AVG 3Y
-16.09%
RETURN ON ASSETS (ROA) AVG 5Y
-46.82%
RETURN ON ASSETS (ROA) AVG 10Y
-43.75%
RETURN ON ASSETS (ROA) AVG 15Y
-25.82%
RETURN ON ASSETS (ROA) AVG 20Y
-27.75%
CURRENT VS TTM AVG
-237.33%
CURRENT VS 3Y AVG
+45.92%
CURRENT VS 5Y AVG
+81.42%
CURRENT VS 10Y AVG
+80.11%
CURRENT VS 15Y AVG
+66.30%
CURRENT VS 20Y AVG
+68.65%
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
+68.98%
vs the sector median at left
Gyre Therapeutics, Inc.
Market Cap
$817.21M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
Market Cap
$812.73M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$809.62M
Return on Assets (ROA)
10.76%
TTM Avg
17.66%
3Y Avg
20.82%
5Y Avg
23.86%
Market Cap
$830.70M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$833.10M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$798.22M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$787.62M
Return on Assets (ROA)
1.14%
TTM Avg
0.56%
3Y Avg
-13.91%
5Y Avg
-9.14%
Market Cap
$853.77M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $817.21M | -8.70% | 6.33% | -16.09% | -46.82% |
| Ardelyx, Inc. (ARDX)vs › | $812.73M | -9.67% | -10.63% | -19.71% | -38.52% |
| InMode Ltd. (INMD)vs › | $809.62M | 10.76% | 17.66% | 20.82% | 23.86% |
| Alumis Inc. (ALMS)vs › | $830.70M | -78.30% | -72.68% | -105.45% | -105.45% |
| Jade Biosciences, Inc. (JBIO)vs › | $833.10M | -32.46% | -61.56% | -55.11% | -72.90% |
| AdaptHealth Corp. (AHCO)vs › | $798.22M | -5.26% | 0.19% | -3.34% | -3.22% |
| Apnimed, Inc. (APMD)vs › | $824.34M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $787.62M | 1.14% | 0.56% | -13.91% | -9.14% |
| Beta Bionics, Inc. (BBNX)vs › | $853.77M | -24.96% | -29.43% | -70.30% | -70.30% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $854.51M | -23.15% | -12.59% | -25.36% | -32.38% |
ROA
-8.7%
ROE
-13.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.03% |
| 2024-12-31 | 9.64% |
| 2023-12-31 | -79.74% |
| 2022-12-31 | 2.72% |
| 2021-12-31 | -157.98% |
| 2020-12-31 | -58.56% |
| 2019-12-31 | -55.99% |
| 2018-12-31 | -24.06% |
| 2017-12-31 | -54.57% |
| 2016-12-31 | -44.49% |
| 2015-12-31 | -21.23% |
| 2014-12-31 | -29.13% |
| 2013-12-31 | -32.02% |
| 2012-12-31 | -3.69% |
| 2011-12-31 | -3.30% |
| 2010-12-31 | 4.15% |
| 2009-12-31 | -12.34% |
| 2008-12-31 | -26.04% |
| 2007-12-31 | -28.37% |
| 2006-12-31 | 2.58% |
| 2005-12-31 | -103.54% |
| 2004-12-31 | -41.28% |
| 2003-12-31 | -40.93% |
| 2002-12-31 | -38.75% |
| 2001-12-31 | -29.93% |
